FDA's policy statement for the development of new stereoisomeric drugs

Chirality. 1992;4(5):338-40. doi: 10.1002/chir.530040513.

PMID: 1354468
DOI: 10.1002/chir.530040513

No abstract available

MeSH terms

Adrenergic beta-Antagonists / chemistry*
Adrenergic beta-Antagonists / metabolism
Adrenergic beta-Antagonists / pharmacokinetics
Animals
Biotransformation
Drug Design*
Humans
Stereoisomerism
United States
United States Food and Drug Administration*

Substances

Adrenergic beta-Antagonists